10-K: Beyond Air, Inc. Navigates Growth with Focus on LungFit Platform and Novel Therapies

Beyond Air, Inc. is advancing its LungFit platform and exploring novel therapies for respiratory, oncological, and neurological conditions, as detailed in its recent annual report.

Summary

• Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide (NO) therapies.
• The company's LungFit PH system, approved by the FDA in 2022, is designed to improve oxygenation in newborns with hypoxic respiratory failure.
• Beyond Air is also developing LungFit PRO for viral lung infections, LungFit GO for nontuberculous mycobacteria (NTM), and exploring NO for solid tumors through its affiliate, Beyond Cancer.
• The company is also developing nNOS inhibitors for neurological conditions like autism spectrum disorder (ASD).
• The company reported a net loss of $64.3 million for the year ended March 31, 2024, and has an accumulated deficit of approximately $239.7 million.
• The company has a loan agreement with Avenue Capital for up to $40 million, with $17.5 million drawn as of March 31, 2024.
• The company is actively seeking additional funding through various means, including equity offerings and strategic partnerships.

Sentiment

Score: 4

Explanation: The document highlights both positive developments in clinical trials and product development, but the significant losses, need for additional funding, and competitive landscape temper the overall sentiment. The company is making progress but faces significant financial and operational challenges.

Positives

• The LungFit platform has multiple potential applications in respiratory diseases.
• The company has completed several successful pilot studies for various indications.
• The company has a strong intellectual property portfolio.
• The company has a seasoned leadership team with experience in emerging healthcare companies and clinical oncology.
• The company has secured a loan agreement with Avenue Capital for up to $40 million.

Negatives

• The company has incurred significant losses since its inception and anticipates continuing to incur losses for the foreseeable future.
• The company is heavily dependent on the success of its approved product and product candidates.
• The company faces intense competition and rapid technological changes.
• The company has a limited operating history and a nascent marketing and sales organization.
• The company is subject to various healthcare laws and regulations, and failure to comply may result in substantial penalties.
• The company is dependent on third-party manufacturers and suppliers.

Risks

• The company may not be able to obtain additional capital on favorable terms or at all.
• The company may not be able to successfully commercialize its approved product or product candidates.
• The company may face challenges in scaling sales and marketing capabilities.
• The company may experience delays or difficulties in clinical trials.
• The company may be subject to product liability claims.
• The company may be subject to cybersecurity breaches and data leakage.
• The company may be subject to healthcare legislative or regulatory reform measures.
• The company may be subject to intellectual property claims.

Future Outlook

The company anticipates continuing to incur significant losses for the foreseeable future and will need to raise additional capital to fund its operations. The company expects to receive CE mark under the Medical Device Regulation (MDR) in the EU during the second half of calendar 2024 and anticipates commencing a pivotal clinical trial for NTM in calendar year 2026 following discussions with the FDA. The company expects its program for nNOS inhibitors to progress into a phase 1 first-in-human clinical trial in calendar year 2025.

Management Comments

• Management believes that the company will require additional funding within one year from the date these financial statements are issued.
• Management is confident that the efforts to arrange financing will enable them to meet the Companys obligations.

Industry Context

The company operates in a highly competitive biotechnology, pharmaceutical, and medical device industry. Several companies are developing NO therapies for various indications, including hypoxic respiratory failure, chronic pulmonary diseases, and skin infections. The company's focus on generating NO from ambient air and delivering high concentrations of NO sets it apart from some competitors.

Comparison to Industry Standards

• Mallinckrodt's INOMAX is a major competitor in the PPHN market, with sales of $298.2 million in 2023, primarily in the U.S.
• Linde Group and Air Liquide also market NO delivery systems, primarily in Europe.
• Bellerophon Therapeutics is developing NO delivery systems for chronic pulmonary diseases.
• VERO Biotech LLC has received FDA approval for their GENOSYL DS delivery system for PPHN.
• Novan Inc. has received approval for a nitric oxide-based prescription treatment called berdazimer for molluscum.
• SaNOtize has an NO nasal spray that has received approval in India, Israel and eight other countries for preventing COVID-19 after exposure.
• Third Pole has reported the development of an NO generator and delivery system, but we are not aware of any display of any product at any medical/scientific conference in recent years.

Legal Proceedings

• The company paid a total of $7.6 million in satisfaction of judgment in resolution of the Empery Suit.
• The company settled a lawsuit with Hudson Bay Master Fund for $3.1 million.

Related Party Transactions

• Members of the Board of Directors and certain executives of the Company are considered related parties to the offering in March 2024 and invested $1.1 million.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures if the company fails to secure additional funding.
• Customers may benefit from the company's innovative NO therapies.
• Suppliers may be affected by the company's financial challenges.
• Creditors face the risk of non-payment if the company fails to meet its obligations.

Next Steps

• The company will continue to refine its commercialization efforts for LungFit PH.
• The company will continue to work toward a potential launch in the EU and globally in 2024 and beyond.
• The company anticipates commencing a pivotal clinical trial for NTM in calendar year 2026 following discussions with the FDA.
• The company expects its program for nNOS inhibitors to progress into a phase 1 first-in-human clinical trial in calendar year 2025.

Key Dates

Keywords

Nitric Oxide, LungFit, PPHN, Viral Pneumonia, Bronchiolitis, NTM, Oncology, Autism, Medical Device, Biopharmaceutical